Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

12 HR Treprostinil 2.5 MG Extended Release Oral Tablet

Known as: treprostinil 2.5 MG 12HR Extended Release Oral Tablet, TREPROSTINIL DIOLAMINE 2.5MG SA TAB, TREPROSTINIL DIOLAMINE 2.5MG TAB,SA [VA Product] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2019
2019
Summary of Objectives Inhalational drug delivery to treat PAH is attractive due to enhanced pulmonary specificity and reduced… Expand
Is this relevant?
2016
2016
INTRODUCTION Severe Raynaud's syndrome and DUs are the most prevalent manifestations of SSc peripheral microvascular disease. We… Expand
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Review
2015
Review
2015
Idiopathic pulmonary arterial hypertension (PAH) is a progressive disease without identifiable etiology and is characterized by… Expand
  • figure 1
  • table 1
Is this relevant?
2013
2013
IntroductionTreprostinil diethanolamine is an innovative salt form of the prostacyclin analogue, treprostinil sodium, developed… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND The Tyvaso Inhalation System is a hand-held nebulizer system used to administer treprostinil, an approved therapy for… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Review
2008
Review
2008
  • 2008
  • Corpus ID: 195105008
 
Is this relevant?